GSK PLC (NYSE:GSK) Maintains Neutral Rating from Citigroup Amidst Positive Developments

Core Viewpoint - Citigroup maintains a Neutral rating for GSK PLC while raising its price target following a significant stock rally and positive investor sentiment [2][6]. Group 1: Financial Performance - GSK's full-year 2025 earnings per share exceeded consensus by 2%, and the 2026 guidance aligns with expectations [2][6]. - Despite trimming its 2026 and 2027 earnings forecasts by 1% to 2% due to foreign exchange challenges and vaccine assumptions, GSK's long-term earnings are considered stable [3][6]. Group 2: Stock Performance - GSK's stock price is currently $58.92, reflecting a decrease of 2.175% or $1.31, with a market capitalization of approximately $118.8 billion [5]. - The stock has traded between $58.61 and $59.94 today, indicating active investor interest with a trading volume of 5,283,039 shares [5]. Group 3: Strategic Developments - Investors have reacted positively to the new CEO, Luke Miels, who is focusing on accelerating research and development and pursuing lower-risk business development [4]. - Recent strategic moves, such as the deal with RAPT Therapeutics, support GSK's efforts to achieve a £40 billion revenue target [4].